NCT04321161View on ClinicalTrials.gov

Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 25, 2020

Primary Completion Date

March 18, 2020

Study Completion Date

March 18, 2020

Conditions
Acute Myeloid Leukemia, in Relapse
Interventions
DRUG

Bicanorm

"Treatment of patients with relapsed AML after allo-HCT receiving DLIs with Bicanorm (1-1-1) for 7 days.~sodium hydrogen carbonate (1 g per 1 tablet) = sodium ion (11,9 mmol per 1 tablet) = sodium ion (273 mg per 1 tablet) = hydrogen carbonate ion (11,9 mmol per 1 tablet)"

Trial Locations (1)

79106

Medical Center University of Freiburg, Freiburg im Breisgau

All Listed Sponsors
lead

University of Freiburg

OTHER

NCT04321161 - Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment | Biotech Hunter | Biotech Hunter